AG490 promotes HIF-1α accumulation by inhibiting its hydroxylation

Area of Science:

• Biochemistry
• Molecular Biology
• Cell Biology

Background:

• AG490 is a known inhibitor of Janus Activated Kinase 2 (JAK2), epidermal growth factor receptor (EGFR), and guanylyl cyclases (GC).
• AG490 has demonstrated protective effects in experimental models of acute kidney injury, possibly linked to oxidative stress modulation.

Purpose of the Study:

• To investigate the mechanism by which AG490 exerts its protective effects.
• To determine if AG490 influences Hypoxia Inducible Factor (HIF)-1 signaling pathways.

Main Methods:

• Assessed HIF-1α protein and mRNA levels in various cell types (endothelial, vascular smooth muscle, kidney proximal tubular epithelial) treated with AG490.
• Investigated the effect of AG490 on HIF-1α protein half-life and degradation pathways, including hydroxylation and VHL-mediated ubiquitination.
• Examined HIF-1α transcriptional activity by measuring VEGF expression.

Main Results:

• AG490 significantly increased HIF-1α protein levels in a dose- and time-dependent manner, without affecting HIF-1α mRNA.
• AG490 prolonged HIF-1α protein half-life by inhibiting its hydroxylation and subsequent VHL-mediated degradation.
• AG490 enhanced HIF-1α transcriptional activity, evidenced by increased VEGF expression.

Conclusions:

• AG490 is identified as a novel activator of HIF-1.
• The activation mechanism involves stabilization of HIF-1α protein through interference with hydroxylation and VHL-mediated degradation.
• This HIF-1 activation may contribute to the observed cell and tissue protective properties of AG490.